Search research articles
Contact Us
Filters
Showing results (51-60 of 127) with videos related to
Page
of 13
Sort By:
Expert Opinion on Biological Therapy
|
February 13, 2018
Subcutaneous semaglutide (NN9535) for the treatment of type 2 diabetes
Maka S Hedrington, Ana Tsiskarishvili, Stephen N Davis
Expert Opinion on Drug Safety
|
November 12, 2025
What is our current understanding of insulin-derived amyloidosis?
Diana Varghese, Kashif M Munir, Stephen N Davis
Expert Review of Endocrinology & Metabolism
|
September 16, 2021
Nocturnal hypoglycemia in type 1 and type 2 diabetes: an update on prevalence, prevention, pathophysiology and patient awareness
Maka Siamashvili, Hugh A Davis, Stephen N Davis
Expert Opinion on Drug Safety
|
June 1, 2019
An update on the safety and efficacy of oral antidiabetic drugs: DPP-4 inhibitors and SGLT-2 inhibitors
Elizabeth Mary Lamos, Maka Hedrington, Stephen N Davis
Expert Opinion on Drug Metabolism & Toxicology
|
April 28, 2011
Pharmacokinetics, efficacy and safety of aleglitazar for the treatment of type 2 diabetes with high cardiovascular risk
Lisa M Younk, Lisa Uhl, Stephen N Davis
American Journal of Physiology. Endocrinology and Metabolism
|
October 18, 2007
Antecedent short-term central nervous system administration of estrogen and progesterone alters counterregulatory responses to hypoglycemia in conscious male rats
Darleen A Sandoval, Bin Gong, Stephen N Davis
Transactions of the American Clinical and Climatological Association
|
August 16, 2014
Mechanisms of hypoglycemia and exercise-associated autonomic dysfunction
Stephen N Davis, Donna Tate, Maka S Hedrington
Expert Opinion on Investigational Drugs
|
September 15, 2015
Immunotherapies currently in development for the treatment of type 1 diabetes
Ian C Davis, Jacqueline Randell, Stephen N Davis
Expert Review of Clinical Pharmacology
|
March 10, 2017
GLP-1 receptor agonists in the treatment of polycystic ovary syndrome
Elizabeth Mary Lamos, Rana Malek, Stephen N Davis
Expert Opinion on Pharmacotherapy
|
May 14, 2011
Pramlintide and the treatment of diabetes: a review of the data since its introduction
Lisa M Younk, Maia Mikeladze, Stephen N Davis
Page
of 13
Search research articles
Search
Showing results (51-60 of 127) with videos related to
Sort By:
Page
of 13
Expert Opinion on Biological Therapy
|
February 13, 2018
Subcutaneous semaglutide (NN9535) for the treatment of type 2 diabetes
Maka S Hedrington, Ana Tsiskarishvili, Stephen N Davis
Expert Opinion on Drug Safety
|
November 12, 2025
What is our current understanding of insulin-derived amyloidosis?
Diana Varghese, Kashif M Munir, Stephen N Davis
Expert Review of Endocrinology & Metabolism
|
September 16, 2021
Nocturnal hypoglycemia in type 1 and type 2 diabetes: an update on prevalence, prevention, pathophysiology and patient awareness
Maka Siamashvili, Hugh A Davis, Stephen N Davis
Expert Opinion on Drug Safety
|
June 1, 2019
An update on the safety and efficacy of oral antidiabetic drugs: DPP-4 inhibitors and SGLT-2 inhibitors
Elizabeth Mary Lamos, Maka Hedrington, Stephen N Davis
Expert Opinion on Drug Metabolism & Toxicology
|
April 28, 2011
Pharmacokinetics, efficacy and safety of aleglitazar for the treatment of type 2 diabetes with high cardiovascular risk
Lisa M Younk, Lisa Uhl, Stephen N Davis
American Journal of Physiology. Endocrinology and Metabolism
|
October 18, 2007
Antecedent short-term central nervous system administration of estrogen and progesterone alters counterregulatory responses to hypoglycemia in conscious male rats
Darleen A Sandoval, Bin Gong, Stephen N Davis
Transactions of the American Clinical and Climatological Association
|
August 16, 2014
Mechanisms of hypoglycemia and exercise-associated autonomic dysfunction
Stephen N Davis, Donna Tate, Maka S Hedrington
Expert Opinion on Investigational Drugs
|
September 15, 2015
Immunotherapies currently in development for the treatment of type 1 diabetes
Ian C Davis, Jacqueline Randell, Stephen N Davis
Expert Review of Clinical Pharmacology
|
March 10, 2017
GLP-1 receptor agonists in the treatment of polycystic ovary syndrome
Elizabeth Mary Lamos, Rana Malek, Stephen N Davis
Expert Opinion on Pharmacotherapy
|
May 14, 2011
Pramlintide and the treatment of diabetes: a review of the data since its introduction
Lisa M Younk, Maia Mikeladze, Stephen N Davis
Page
of 13